EPCAM and microtia: Currently, several II/III stage clinical trials (NCT01320020, NCT00822809, NCT00836654, etc.)have shown that BiTE catumaxomab (Anti-EpCAM x Anti-CD3) can effectively improve the quality of life and survival time of malignant ascites (MA) from ovarian and nonovarian (including gastric, pancreatic, and breast, etc.)cancer patients 120-122.